Navigation Links
Seroquel Sustained Release Schizophrenia Data Presented at ECP,Congress in Madrid

new SEROQUEL® sustained release formulation studies presented at the congress show that patients who are currently receiving original formulation quetiapine, or who are inadequately treated with another antipsychotic agent, could be easily switched to SEROQUEL® sustained release formulation. Among clinically stable patients who switched from original formulation quetiapine, there were no significant differences between SEROQUEL sustained release formulation and the original formulation quetiapine in PANSS total scores after six weeks’ treatment (mean PANSS total score at day 42 was 55.4 and 54.8 for the sustained release formulation and the original formulation respectively) and the incidence of adverse events was similar (Study 146). Among patients who switched to SEROQUEL® sustained release formulation from other antipsychotics, 62.8 percent achieved improved clinical benefit (based on CGI-CB scores) regardless of the reason for switching (insufficient efficacy or intolerability of initial treatment, Study 147).

Based on these data and data from other trials, regulatory filings for the treatment of schizophrenia with SEROQUEL® sustained release formulation were submitted to the authorities in the US, EU and other markets in 2006. Beyond schizophrenia, ongoing clinical studies of SEROQUEL® sustained release formulation cover bipolar disorder, major depressive disorder and generalised anxiety disorder. SEROQUEL® (original formulation quetiapine) is the number one prescribed atypical antipsychotic in the United States and global sales for SEROQUEL® reached $3.4 billion in 2006. It is licensed in 85 countries for the treatment of schizophrenia, in 73 countries for the treatment of mania associated with bipolar disorder, and in October 2006 it was approved in the US by the FDA for the treatment of bipolar depression. It is estimated that more than 19 million patients have used SEROQUEL® worldwide since its launch in 1997.'"/>




Page: 1 2 3 4

Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
3. OREXIGEN Therapeutics Announces Sustained-Release Formulation of Zonisamide Shows Improved Tolerability When Compared to Immediate Release Formulation
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
6. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
7. Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
10. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
11. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
Post Your Comments:
(Date:10/1/2014)... 2014   Plexus Information Systems, Inc. ... Management Systems (AIMS), announced a partnership with ... owned subsidiary of Quality Systems, Inc. and a ... solutions.  Logo - http://photos.prnewswire.com/prnh/20140930/149406 ... This partnership extends the NextGen Healthcare product ...
(Date:10/1/2014)... -- NeuroCall, Inc., ("NeuroCall") announced today that it recently ... services. Dr. Ricardo Garcia-Rivera , Founder and Chief ... that our quality of service has been recognized by ... support and continuity of care to patients of our ... United States ." NeuroCall currently ...
(Date:10/1/2014)... SAN MARCOS, Texas , Oct. 1, 2014 ... that it is scaling volume production of photoactive ... solar power technologies . While offering numerous advantages ... difficulty of producing large quantities of quantum dots ... has until now kept them from commercial utilization ...
Breaking Medicine Technology:Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3NeuroCall Awarded Joint Commission Accreditation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3
(Date:10/1/2014)... Philadelphia, PA, October 1, 2014 Patients with ... treatment, have a greatly increased risk of depression. ... therapy for chronic hepatitis C virus infection causes ... Omega-3 fatty acids, more commonly known as fish ... including lowering the risk of heart disease and ...
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog post explaining ... , Senior citizens can purchase a joint life insurance ... A joint policy is cheaper, but will only pay ... Life insurance can be used to cover important funeral ... online, as the application process is simple and straightforward. ...
(Date:10/1/2014)... First Warning Systems, a pioneer in ... throughout the body, announced the company is changing its ... company’s breadth of upcoming product releases. The initial focus ... , “Our initial focus will be an ‘Internet of ... circadian cellular changes over time,” said Rob Royea, president ...
(Date:10/1/2014)... 01, 2014 Join the more than 80 ... Treatment Center’s first ever charity golf tournament to benefit Project ... eating disorders who cannot afford treatment. The tournament will be ... Eureka, Mo. , The day-long event starts with 10:30 ... and award dinner will begin at 5 p.m. and will ...
(Date:10/1/2014)... 2014 Innovations announces the upcoming airing ... on Monday, October 20, 2014 at 7:30 a.m. EST/PT ... go behind the scenes to learn about Break the ... explore the practical help and information Break the Cycle ... warning signs of abuse, how to navigate the legal ...
Breaking Medicine News(10 mins):Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2
... four months of hormonal therapy before and with ... by as much as eight yearsespecially the development ... with potentially aggressive prostate cancer. This neoadjuvant hormonal ... developing bone metastases avoid long-term hormonal therapy later ...
... immune cells seems to halt the cells typical job ... study by Johns Hopkins researchers suggests. The findings ... ranging from annoying bouts of hay fever to deadly ... his colleagues at the Johns Hopkins Asthma and Allergy ...
... most common cause of disability in the United States. ... continues to age, the toll of this disease will escalate. ... burden and its impact on our nations health care and ... by any form of arthritisis critical. , The National Arthritis ...
... 2008) Athanasios Zavras began receiving messages from distraught ... meds to bone death in the jaw. A number ... these drugs to postpone dental work, fearing that procedures ... when Zavras, an associate professor in the Harvard School ...
... (ACP) has received a Commonwealth Fund grant of nearly $225,000 ... The grant, part of the Commonwealth Funds Patient-Centered Primary ... in November. ACP committed matching funds late in 2007. ... goal is to put the needs of the patient first. ...
... use of opioid drugs to relieve severe pain, black ... to receive these pain-relievers in emergency rooms, according to ... for more than 150,000 pain-related visits to U.S. hospitals ... of whites received opioid drugs compared with only 23 ...
Cached Medicine News:Health News:Just 4 months of hormone therapy can delay prostate cancer growth by up to 8 years 2Health News:Protein a possible key to allergy and asthma control 2Health News:Protein a possible key to allergy and asthma control 3Health News:The prevalence and impact of arthritis and other rheumatic conditions in the United States 2Health News:The prevalence and impact of arthritis and other rheumatic conditions in the United States 3Health News:Oral osteoporosis meds appear to reduce the risk of jaw degradation 2Health News:American College of Physicians receives grant to study cost of patient-centered medical home 2Health News:Blacks, Hispanics less likely to get strong pain drugs in emergency rooms 2
... Sun Med TruFlow™ Oxygen flowmeter with a ... warranty covering calibration and manufacturing defects. A ... meet most needs. Also available with all ... power take-off and double unit configurations. Our ...
... adults, the entire series of time-tested Timeter® ... the needs of care providers and patients ... accuracy. You can see it in the ... performance, year after year. Every Timeter® Classic ...
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
Medicine Products: